Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 24

1.

Idiopathic Brachial Neuritis in a Patient with Multiple Myeloma.

Cerrahoglu L, Erol O, Sirin TC.

J Clin Diagn Res. 2017 Jun;11(6):OD11-OD12. doi: 10.7860/JCDR/2017/22426.10082. Epub 2017 Jun 1.

2.

Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy.

Dingli D, Ailawadhi S, Bergsagel PL, Buadi FK, Dispenzieri A, Fonseca R, Gertz MA, Gonsalves WI, Hayman SR, Kapoor P, Kourelis T, Kumar SK, Kyle RA, Lacy MQ, Leung N, Lin Y, Lust JA, Mikhael JR, Reeder CB, Roy V, Russell SJ, Sher T, Stewart AK, Warsame R, Zeldenrust SR, Rajkumar SV, Chanan Khan AA.

Mayo Clin Proc. 2017 Apr;92(4):578-598. doi: 10.1016/j.mayocp.2017.01.003. Epub 2017 Mar 11. Review.

3.

Upfront autologous stem cell transplantation for newly diagnosed elderly multiple myeloma patients: a prospective multicenter study.

Garderet L, Beohou E, Caillot D, Stoppa AM, Touzeau C, Chretien ML, Karlin L, Moreau P, Fontan J, Blaise D, Polge E, Gueye MS, Ikhlef S, Marjanovic Z, Labopin M, Mohty M.

Haematologica. 2016 Nov;101(11):1390-1397. Epub 2016 Sep 9.

4.

Recent advances in multiple myeloma: a Korean perspective.

Hong J, Lee JH.

Korean J Intern Med. 2016 Sep;31(5):820-34. doi: 10.3904/kjim.2015.408. Epub 2016 Sep 1. Review.

5.

Challenges in multiple myeloma diagnosis and treatment.

Girnius S, Munshi NC.

Leuk Suppl. 2013 May;2(Suppl 1):S3-9. doi: 10.1038/leusup.2013.2. Epub 2013 May 8. Review.

6.

Advances in treatment for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation.

San Miguel JF, Mateos MV.

Leuk Suppl. 2013 May;2(Suppl 1):S21-7. doi: 10.1038/leusup.2013.5. Epub 2013 May 8. Review.

7.

Risk of Second Primary Cancers in Multiple Myeloma Survivors in German and Swedish Cancer Registries.

Chen T, Fallah M, Brenner H, Jansen L, Mai EK, Castro FA, Katalinic A, Emrich K, Holleczek B, Geiss K, Eberle A, Sundquist K, Hemminki K; GEKID Cancer Survival Working Group.

Sci Rep. 2016 Feb 24;6:22084. doi: 10.1038/srep22084.

8.
9.

A Case of Posterior Mediastinal Plasmacytoma Confounded by Community-Acquired Pneumonia.

Heo D, Boo KY, Jwa H, Lee HY, Kim J, Kim ST, Seo HM, Han SH, Maeng YH, Lee JH.

Tuberc Respir Dis (Seoul). 2015 Jul;78(3):262-6. doi: 10.4046/trd.2015.78.3.262. Epub 2015 Jun 30.

10.

Autologous Hematopoietic Stem Cell Transplantation-10 Years of Data From a Developing Country.

Ali N, Adil SN, Shaikh MU.

Stem Cells Transl Med. 2015 Aug;4(8):873-7. doi: 10.5966/sctm.2015-0015. Epub 2015 Jun 1.

11.

Shoulder pad sign and asymptomatic hypercalcemia in a patient with end-stage kidney disease.

Izawa S, Akimoto T, Ikeuchi H, Kusano E, Nagata D.

Clin Med Insights Case Rep. 2015 Mar 15;8:27-31. doi: 10.4137/CCRep.S21848. eCollection 2015.

12.

Early versus deferred treatment for smoldering multiple myeloma: a meta-analysis of randomized, controlled trials.

Gao M, Yang G, Tompkins VS, Gao L, Wu X, Tao Y, Hu X, Hou J, Han Y, Xu H, Zhan F, Shi J.

PLoS One. 2014 Oct 3;9(10):e109758. doi: 10.1371/journal.pone.0109758. eCollection 2014.

13.

Bortezomib in multiple myeloma: systematic review and clinical considerations.

Kouroukis TC, Baldassarre FG, Haynes AE, Imrie K, Reece DE, Cheung MC.

Curr Oncol. 2014 Aug;21(4):e573-603. doi: 10.3747/co.21.1798. Review.

14.

Pomalidomide for the treatment of multiple myeloma.

Clark SM, Steinbach A, Clemmons AB.

J Adv Pract Oncol. 2014 Jan;5(1):51-6. Review. No abstract available.

15.

Efficacy of lenalidomide in association with cyclophosphamide and dexamethasone in multiple myeloma patient with bilateral retro-orbital localisation.

Felici S, VillivĂ  N, Balsamo G, Andriani A.

Ecancermedicalscience. 2013 Jul 10;7:331. doi: 10.3332/ecancer.2013.331. eCollection 2013.

16.

Staging and prognostication of multiple myeloma.

Fonseca R, Monge J, Dimopoulos MA.

Expert Rev Hematol. 2014 Feb;7(1):21-31. doi: 10.1586/17474086.2014.882224. Review.

17.

International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation.

Palumbo A, Rajkumar SV, San Miguel JF, Larocca A, Niesvizky R, Morgan G, Landgren O, Hajek R, Einsele H, Anderson KC, Dimopoulos MA, Richardson PG, Cavo M, Spencer A, Stewart AK, Shimizu K, Lonial S, Sonneveld P, Durie BG, Moreau P, Orlowski RZ.

J Clin Oncol. 2014 Feb 20;32(6):587-600. doi: 10.1200/JCO.2013.48.7934. Epub 2014 Jan 13. Review.

18.

Multiple myeloma: an update.

Al-Farsi K.

Oman Med J. 2013 Jan;28(1):3-11. doi: 10.5001/omj.2013.02.

19.

Early response to bortezomib combined chemotherapy can help predict survival in patients with multiple myeloma who are ineligible for stem cell transplantation.

Lee HS, Kim YS, Kim K, Kim JS, Kim HJ, Min CK, Suh C, Eom HS, Yoon SS, Lee JH, Kim MK, Kim SH, Bae SH, Mun YC, Jo DY, Chung JS; Korean Multiple Myeloma Working Party (KMMWP).

J Korean Med Sci. 2013 Jan;28(1):80-6. doi: 10.3346/jkms.2013.28.1.80. Epub 2013 Jan 8.

20.

Supplemental Content

Support Center